Ten-Day versus 14-Day Levofloxacin-Containing Triple Therapy for Second-Line Anti-Helicobacter pylori Eradication in Taiwan

Table 4

Univariate analysis of the clinical factors influencing the efficacy of Helicobacter  pylori eradication.

Principle parameter	Case no.	Eradication rate	𝑃 value
Age
<60 years	111	82.0% (91)	0.318
≥60 years	72	87.5% (63)
Sex
Female	98	81.6% (80)	0.316
Male	85	87.1% (74)
Smoking
(−)	168	83.3% (140)	0.472
(+)	15	93.3% (14)
Previous history of peptic ulcer
(−)	138	81.9% (113)	0.141
(+)	45	91.1% (41)
HP eradication (per protocol)
EAL-10	90	75.6% (68)	0.002
EAL-14	93	92.5% (86)
Compliance
Good	183	84.2% (154)	—
Poor	0	0% (0)

EAL-10: esomeprazole/amoxicillin/levofloxacin triple therapy × 10 days and EAL-14: esomeprazole/amoxicillin/levofloxacin triple therapy × 14 days.